Your NEJM Group Today: Ice-Pack Test for Myasthenia Gravis, Childhood BMI & Later Psychosocial Health, Massachusetts Urgent Care Opportunities (FREE)

By the Editors NEJM Group offers so many valuable resources for practicing clinicians. Here's what we chose for you today:NEJM Clinical Practice Center: Image in Clinical Medicine: …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news

Related Links:

We describe a 16-year-old female who presented to our clinic with 1-month complaints of diplopia and strabismus, visual acuity deterioration, and ocular irritation. Her examination showed crossed diplopia and alternating exotropia of 25 prism diopters, severe blepharitis, conjunctival hyperemia, corneal pannus, epithelial irregularities, and subepithelial opacities. Workup included pediatric neurologic examination, laboratory tests, imaging, and electrophysiological tests. Diagnoses of OMG and blepharitis with ocular surface disease were made. Topical treatment included eyelid hygiene, tea tree oil scrubbing, topical stero...
Source: Case Reports in Ophthalmology - Category: Opthalmology Source Type: research
Variants in the SLC25A1 gene are associated with a severe neurometabolic disease, D-2- and L-2-hydroxyglutaric aciduria (D/L-2-HGA). A report in 2014 presented the first account of congenital myasthenic syndrome ...
Source: BMC Neurology - Category: Neurology Authors: Tags: Case report Source Type: research
When the diagnosis of myasthenia gravis (MG) has been secured, the aim of management should be prompt symptom control and the induction of remission or minimal manifestations. Symptom control, with acetylcholinesterase inhibitors such as pyridostigmine, is commonly employed. This may be sufficient in mild disease. There is no single universally accepted treatment regimen. Corticosteroids are the mainstay of immunosuppressive treatment in patients with more than mild MG to induce remission. Immunosuppressive therapies, such as azathioprine are prescribed in addition to but sometimes instead of corticosteroids when backgroun...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Publication date: September 2020Source: Biomedicine &Pharmacotherapy, Volume 129Author(s): Wei Jiao, Fangyu Hu, Jinqiu Li, Jingwei Song, Jian Liang, Lanqi Li, Yafang Song, Zhiwei Chen, Qing Li, Lingling Ke
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
The objective of our study was to assess the tolerability and efficacy of rituximab use in children with refractory JMG.
Source: Pediatric Neurology - Category: Neurology Authors: Tags: Short Communication Source Type: research
AbstractThe robotic approach in the treatment of thymus diseases has been described in many papers, but few studies have compared the early outcome of patients after robotic and open transsternal procedure. Our study aims to confirm the non-inferiority of the robotic technique in terms of feasibility, safety and postoperative patient recovery compared to the open standard. This is a retrospective cohort study in which we compare 114 patients who underwent thymectomy for a thymus disease at our thoracic surgery unit. Our robotic surgery programme started in February 2012 with the treatment of mediastinal diseases. Since the...
Source: Journal of Robotic Surgery - Category: Surgery Source Type: research
Conclusion: With NIV, intubation was prevented in 7 and reintubation in 3 patients. NIV has lower incidence of complications. NIV should be tried in patients with impending MC.
Source: Neurology India - Category: Neurology Authors: Source Type: research
Publication date: Available online 3 July 2020Source: Stem Cell ResearchAuthor(s): Nidaa A. Ababneh, Ban Alkurdi, Dema Ali, Duaa Abuarqoub, Raghda Barham, Abdi T. Ryalat, Abdalla Awidi
Source: Stem Cell Research - Category: Stem Cells Source Type: research
Hendricks TM, Bhatti MT, Hodge DO, Chen JJ. Incidence, Epidemiology, and Transformation of Ocular Myasthenia Gravis: A Population-Based Study. Am J Ophthalmol 2019;205:99 –105.
Source: American Journal of Ophthalmology - Category: Opthalmology Tags: Corrigendum Source Type: research
Authors: Yilmaz V, Ulusoy C, Hajtovic S, Turkoglu R, Kurtuncu M, Tzartos J, Lazaridis K, Tuzun E Abstract Antigen-specific immune responses are crucially involved in both multiple sclerosis (MS) and myasthenia gravis (MG). Teriflunomide is an immunomodulatory agent approved for treatment of MS through inhibition of lymphocyte proliferation. MG associated with muscle-specific tyrosine kinase (MuSK) antibodies often manifests with a severe disease course, prompting development of effective treatment methods. To evaluate whether teriflunomide treatment may ameliorate MuSK-autoimmunity, experimental autoimmune MG (EAMG...
Source: Immunological Investigations - Category: Allergy & Immunology Tags: Immunol Invest Source Type: research
More News: Myasthenia Gravis | Primary Care